In recently conducted studies in a well-established rodent model – an imiquimod-induced skin inflammation model– Aqilion’s lead substance in the TAK1 program demonstrated a significant improvement in all outcome measures. The results are superior to those achieved with corticosteroid-based positive controls. The compelling results indicate that inhibition of TAK1 applied directly to the skin, may provide significant therapeutic benefits in several severe chronic skin diseases. The company is now continuing development towards a well-characterized drug candidate, an optimized topical formulation, and preparations for IND enabling tox and Phase 1 studies.

“The results underscore that TAK1 is a highly interesting target for development of new drugs against chronic inflammation. The possibility of administering our drug candidate topically opens completely new development paths in several severe diseases caused by chronic inflammation or dysfunctional immunological reactions in the skin. We see great potential with this first-in-class, highly potent, non-steroidal treatment option for a wide range of dermatological conditions and look forward to presenting our new data at the BIO conference,” says Sarah Fredriksson, CEO of Aqilion.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com